lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
== Ex vivo or in vivo methods == Methods that screen protein–protein interactions in the living cells. Bimolecular fluorescence complementation (BiFC) is a technique for observing the interactions of proteins. Combining it with other new techniques, dual expression recombinase based (DERB) methods can enable the screening of protein–protein interactions and their modulators. The yeast two-hybrid screen investigates the interaction between artificial fusion proteins inside the nucleus of yeast. This approach can identify the binding partners of a protein without bias. However, the method has a notoriously high false-positive rate, which makes it necessary to verify the identified interactions by co-immunoprecipitation.
Bicalutamide: A pure antiandrogen. It is effective similarly to flutamide but is much safer as well as better-tolerated. Birth control pills that consist of an estrogen, usually ethinylestradiol, and a progestin are supported by the evidence. They are functional antiandrogens. In addition, certain birth control pills contain a progestin that also has antiandrogenic activity. Examples include birth control pills containing cyproterone acetate, chlormadinone acetate, drospirenone, and dienogest. Cyproterone acetate: A dual antiandrogen and progestogen. In addition to single form, it is also available in some formulations of combined oral contraceptives at a low dosage (see below). It has a risk of liver damage. Eflornithine: Blocks putrescine that is necessary for the growth of hair follicles. Finasteride and dutasteride: 5α-Reductase inhibitors. They inhibit the production of the potent androgen DHT. A meta-analysis showed inconsistent results of finasteride in the treatment of hirsutism. Flutamide: A pure antiandrogen. It has been found to possess equivalent or greater effectiveness than spironolactone, cyproterone acetate, and finasteride in the treatment of hirsutism. However, it has a high risk of liver damage and hence is no longer recommended as a first- or second-line treatment. Flutamide is safe and effective. GnRH analogues: Suppress androgen production by the gonads and reduce androgen concentrations to castrate levels. Metformin: Insulin sensitizer.
Type 1 and 2 5α reductase enzymes are present at pilosebaceous units in papillae of individual hair follicles. They catalyse formation of the androgens testosterone and DHT, which in turn regulate hair growth. Androgens have different effects at different follicles: they stimulate IGF-1 at facial hair, causing hair regrowth, but stimulate TGF β1, TGF β2, dickkopf1 and IL-6 at the scalp, causing hair follicle miniaturisation. Female androgenic alopecia is characterized by diffuse crown thinning without hairline recession, and like its male counterpart rarely leads to total hair loss. Finasteride and minoxidil are usually first line therapy for its treatment. Other options include topical or systemic spironolactone or flutamide, although they have a high incidence of feminising side effects and are better tolerated in female androgenic hair loss. More advanced cases may be resistant or unresponsive to medical therapy, however, and require hair transplantation. Naturally occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in close proximity and in large numbers. The grafts are obtained from either Follicular Unit Transplantation (FUT) – colloquially referred to as "strip harvesting" – or Follicular Unit Extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts. The surgeon then implants the grafts into small incisions, called recipient sites.
== Function == Erection occurs through parasympathetic innervation, which allows engorgement of the corporal bodies; the bulbospongiosus and ischiocavernosus muscles at the root compress the veins and prevent blood draining from the corpora cavernosa. Following ejaculation, sympathetic stimulation constricts the coiled helicine arteries and the two muscles relax, allowing the cavernous spaces to drain and the penis to become flaccid. The strength and inflexibility of the tunica albuginea covering the corpora blocks venous return and is therefore responsible for maintaining rigidity during an erection.
Michel Eugène Chevreul (French pronunciation: [miʃɛl øʒɛn ʃəvʁœl]; 31 August 1786 – 9 April 1889) was a French chemist whose work contributed to significant developments in science, medicine, and art. Chevreul's early work with animal fats revolutionized soap and candle manufacturing and led to his isolation of the heptadecanoic (margaric), stearic, and oleic fatty acids. In the process, Chevreul became the first scientist to define the concept of a chemical compound and the first to formally characterize the nature of organic compounds; he is consequently considered a founder of modern organic chemistry. In the medical field, Chevreul was first to demonstrate that diabetics excrete glucose in the urine and to isolate creatine. Chevreul's study of textile dyes while director of the Gobelins Manufactory in Paris led to color theories that "provided the scientific basis for Impressionist and Neo-Impressionist painting." Chevreul is one of the 72 French scientists, mathematicians, and engineers whose names are inscribed on the Eiffel Tower. He lived to be 102 and was a pioneer in the field of gerontology.
Sources: en.wikipedia.org
With the advent of the declaration and the British entry into Jerusalem on 9 December, the Vatican reversed its earlier sympathetic attitude to Zionism and adopted an oppositional stance that was to continue until the early 1990s.
The main use of sulfur for therapeutic purposes has been, throughout history, to cure people and domestic animals of a wide range of skin conditions and parasites. To this day, it remains a popular treatment to alleviate such conditions as scabies, ringworm, psoriasis, eczema, and acne. The exact mechanism of action is unknown, but it is thought to react with the cysteine in the skin to produce hydrogen sulfide, which has antifungal, antioxidant and keratolytic properties, as well as converting to pentathiolic acid, which is antifungal, when applied to the skin. In 1696, Haarlem oil (colloquially known as "Dutch drops"), a sulfur-based potion, was created in Haarlem. Initially sold as a kidney diuretic, it acquired a reputation for being a panacea, and was popularized in other countries by sailors, among whom it was widely used. It is still commercialized three centuries later, and is now often used as a health supplement for horses.
=== Ribosomal RNA === The secondary structure of 23S is divided into six large domains, within which domain V is most important in its peptidyl transferase activity. Each domain contains normal secondary structure (e.g., base triple, tetraloop, cross-strand purine stack) and is also highly symmetric in tertiary structure; proteins intervene between their helices. At tertiary structure level, the large subunit rRNA is a single gigantic domain while the small subunit contains three structural domains. This difference reflects the lesser flexibility of the large subunit required by its function. While its core is conserved, it accommodates expansion segments on its periphery.
The Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS) is annually awarded to author(s) of outstanding scientific paper published in the Research Articles or Reports sections of Science. Established in 1923, funded by Newcomb Cleveland who remained anonymous until his death in 1951, and for this period it was known as the AAAS Thousand Dollar Prize. "The prize was inspired by Mr. Cleveland's belief that it was the scientist who counted and who needed the encouragement an unexpected monetary award could give." The present rules were instituted in 1975, previously it had gone to the author(s) of noteworthy papers, representing an outstanding contribution to science, presented in a regular session, sectional or societal, during the AAAS Annual Meeting. It is now sponsored by the Fodor Family Trust and includes a prize of $25,000. The prize's current sponsorship has a notable connection to a past winner: Stephen P. A. Fodor, founder of Affymetrix, received the prize in 1990 for a paper introducing microarray technology. Affymetrix added its support to the prize in 2003, more than doubling its monetary value at the time. Winners receive a bronze medal, a share of the prize money, and reimbursement for travel to the AAAS Annual Meeting. Final selection is determined by a panel of distinguished scientists appointed by the editor-in-chief of Science. The annual contest period runs from the first issue of June through the last issue of the following May. No prize was awarded in 1942–1945, 1948, 1973, 1975, or 1976.
== Research and Development == The Company has set up a Research & Development (R & D) Centre at Goa. The R & D Centre concentrates on developing NDDS for generic APIs and NCEs, reverse engineering the API processes, drug discovery and bio catalysis. The Company has strategic alliances with global players for CRAMS and other projects. The Company has a functional Biotech R&D Centre and a Pilot Plant at Goa. Bio-similar R&D is based on recombinant DNA platform. Microbial fermentation and protein purification are its strengths. The cell culture facility in the Biotech R&D is capable of handling mammalian cell lines for screening novel biological and chemical entities. The Company has made more than 500 product registrations across the world. It has more than 70 US ANDA filings, 45 approved ANDAs and more than 60 European submissions. The Company holds 75 US DMF, 26 Certificate of suitability to European Pharmacopeia (CEP) issued by the European Directorate for the Quality of Medicines and Healthcare (EDQM) and several DMFs across the world.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.